Evidence map›Paper›PMID 34964177›Full record

ArticleJournal of clinical laboratory analysis2022

Significance of serum miR-29a in the occurrence and progression of diabetic nephropathy: A cross-sectional study.

Qian Liu, Menglin Wang, Tongdao Xu, Wei Liang, Fumeng Yang

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical laboratory analysis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 3 pooled it
0.5field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 3 syntheses or guidelines pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Qian LiuDepartment of Laboratory Medicine, The Second People's Hospital of Lianyungang, Lianyungang, China.
Menglin WangDepartment of Laboratory Medicine, Suqian First Hospital, Suqian, China.
Tongdao XuDepartment of Endocrinology, The Second People's Hospital of Lianyungang, Lianyungang, China.
Wei LiangDepartment of Laboratory Medicine, The Second People's Hospital of Lianyungang, Lianyungang, China.
Fumeng YangDepartment of Laboratory Medicine, The Second People's Hospital of Lianyungang, Lianyungang, China.ORCID https://orcid.org/0000-0002-2636-7340
Jiangsu University · CNSuizhou Central Hospital · CNThe First People’s Hospital of Lianyungang · CN

Funding

Jiangsu Commission of Health M2020079Key Project of the Natural Science Foundation of Bengbu Medical College 2020byzd342Lianyungang Second People's Hospital TQ202101
6 · The paper itself

Abstract

backgroundDiabetic nephropathy (DN), a common microvascular complication of type 2 diabetes mellitus (T2DM), is an important factor causing chronic kidney disease. However, the relationship between miR-29a and DN remains unknown. Therefore, a cross-sectional study was conducted to identify a potential molecular biomarker for DN prevention and management by detecting the serum miR-29a levels.

methodsThe serum miR-29a levels were measured in 360 subjects (180 T2DM patients and 180 healthy controls) using quantitative reverse transcription PCR (qRT-PCR), and other conventional indicators were measured and analysed. A binary logistic regression was used to evaluate the DN risk factors; a receiver operating characteristic (ROC) curve was applied to analyse the diagnostic efficacy of miR-29a for DN, and a Spearman's rank correlation analysis was used to evaluate the correlation between serum miR-29a and cystatin C.

resultsThe serum miR-29 levels in the T2DM patients were higher than those in the healthy subjects and significantly increased with the progression of DN (p < 0.05). Serum miR-29a and cystatin C are independent predictors of the occurrence of DN. Compared with a single indicator, the combination of serum miR-29a and cystatin C has better DN diagnostic performance. In addition, the serum miR-29a levels were positively correlated with cystatin C in the patients with DN (r = 0.521, p < 0.001).

conclusionThe expression of serum miR-29a was significantly associated with the occurrence and progression of DN and is expected to become a potential biomarker for the diagnosis of DN.

Indexed as

AdultBiomarkersCase-Control StudiesCross-Sectional StudiesCystatin CDiabetes Mellitus, Type 2Diabetic NephropathiesDisease ProgressionFemaleHealthy VolunteersHumansLogistic ModelsMaleMicroRNAsMiddle AgedReverse Transcriptase Polymerase Chain ReactionBiomarkersCystatin CMicroRNAsMIRN29a microRNA, humandiabetic nephropathymiR-29amiRNAqRT-PCRtype 2 diabetes mellitus

Identifiers

PMID34964177
PMCPMC8842137
OpenAlexW4200353060

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.